Heparin derivatives having improved anti-Xa specificity

Details Heparin derivatives having improved anti-Xa specificity Heparin derivatives having improved anti-Xa specificity

1986-08-20

1988-05-17

Rollins, John

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514822, 536 21, A61K 31725, C08B 3710

Patent

active

047451068

ABSTRACT:
Acetyl ester derivatives of heparin are disclosed. These derivatives exhibit improved Anti-Xa activity in relation to their global anticlotting activity.

REFERENCES:
patent: 3835112 (1971-06-01), Mardiguian
patent: 4281108 (1981-07-01), Fussi
patent: 4303651 (1981-12-01), Lindahl
patent: 4331697 (1982-03-01), Kudo et al.
patent: 4351938 (1982-09-01), Barnett
patent: 4396762 (1983-08-01), Langer
patent: 4401662 (1983-08-01), Lormeau
patent: 4401758 (1983-08-01), Lormeau
patent: 4415559 (1983-11-01), Suzuki
patent: 4438108 (1984-03-01), Sanders
patent: 4438261 (1984-03-01), Barnett
patent: 4440926 (1984-04-01), Mardiguian
patent: 4474770 (1984-10-01), Lormeau
patent: 4486420 (1984-12-01), Lormeau
patent: 4500519 (1985-02-01), Lormeau
patent: 4533549 (1985-08-01), Lasker

Affiliated with

Also associated with

Rating

Heparin derivatives having improved anti-Xa specificity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heparin derivatives having improved anti-Xa specificity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heparin derivatives having improved anti-Xa specificity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1881485